Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Triton Fund II in connection with the sale of Bravida
Mandate

Vinge advises Triton Fund II in connection with the sale of Bravida

May 16, 2012

Vinge has advised Triton Fund II and the minority shareholders in connection with the sale of the Bravida Group, the leading group in Scandinavia within technical installations and services for real estate to Bain Capital.  Triton has owned Bravida, which has approximately 8 000 employees and a turnover last year of SEK 10.8 billion, since 2006.

Vinge’s team was led by responsible partner, Christina Kokko and also consisted of partners Peter Bäärnhielm and Charlotte Levin, associates Paul Dali, Jo-Anna Nordström, Nicolina Kindblom, Rikard Lindahl, Louise Brorsson Salomon, Albert Wållgren and several lawyers from Vinge’s specialist practice groups and project assistant Ida Norlin.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026